Literature DB >> 24980389

Recurrent cellulitis: risk factors, etiology, pathogenesis and treatment.

Maciej Piotr Chlebicki1, Choon Chiat Oh.   

Abstract

Erysipelas and uncomplicated cellulitis are common infections that tend to recur in a substantial proportion of affected patients following an initial episode, especially if the predisposing condition is chronic lymphedema. All patients who suffer an episode of cellulitis should be carefully evaluated to establish the risk of recurrence. Several predisposing conditions (such as lymphedema and skin conditions that serve as a portal of entry for bacteria) can be effectively treated in order to reduce the risk of relapse. The medical literature provides convincing evidence that antimicrobial prophylaxis can markedly reduce the frequency of relapse of erysipelas. Two recent studies performed by the 'Prophylactic Antibiotics for the Treatment of Cellulitis at Home' (PATCH) group have clearly confirmed the efficacy of antimicrobial prophylaxis. Penicillin remains the drug of choice. Treatment options in patients with penicillin allergy are limited by the rising prevalence of macrolide resistance among group A streptococci. Further research is required to clarify the optimal penicillin regimen as well as to develop new therapies for patients with allergy to penicillin.

Entities:  

Year:  2014        PMID: 24980389     DOI: 10.1007/s11908-014-0422-0

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  74 in total

1.  Lymphoscintigraphic evaluation in patients after erysipelas.

Authors:  J M de Godoy; M F de Godoy; A Valente; E L Camacho; E V Paiva
Journal:  Lymphology       Date:  2000-12       Impact factor: 1.286

Review 2.  Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review.

Authors:  Claudia Thomas; Mark Stevenson; Thomas V Riley
Journal:  J Antimicrob Chemother       Date:  2003-05-13       Impact factor: 5.790

3.  Recurrent erysipelas: predisposing factors and costs of prophylaxis.

Authors:  C Jorup-Rönström; S Britton
Journal:  Infection       Date:  1987 Mar-Apr       Impact factor: 3.553

4.  Rheumatic fever following streptococcal vaccination. Report of three cases.

Authors:  B F Massell; L H Honikman; J Amezcua
Journal:  JAMA       Date:  1969-02-10       Impact factor: 56.272

5.  Prophylactic antibiotics in erysipelas.

Authors:  T Duvanel; Y Mérot; M Harms; J H Saurat
Journal:  Lancet       Date:  1985-06-15       Impact factor: 79.321

Review 6.  Breast cellulitis complicating breast conservation therapy.

Authors:  L M Baddour
Journal:  J Intern Med       Date:  1999-01       Impact factor: 8.989

7.  Domains of group A streptococcal M protein that confer resistance to phagocytosis, opsonization and protection: implications for vaccine development.

Authors:  Jason D McArthur; Mark J Walker
Journal:  Mol Microbiol       Date:  2006-01       Impact factor: 3.501

8.  [Therapy and prophylaxis of recurrent erysipelas (author's transl)].

Authors:  A Ziebart-Schroth
Journal:  Med Klin       Date:  1976-07-09

9.  Incidence of erysipelas following venectomy for coronary artery bypass surgery.

Authors:  M Dan; K Heller; I Shapira; B Vidne; S Shibolet
Journal:  Infection       Date:  1987 Mar-Apr       Impact factor: 3.553

10.  Penicillin to prevent recurrent leg cellulitis.

Authors:  Kim S Thomas; Angela M Crook; Andrew J Nunn; Katharine A Foster; James M Mason; Joanne R Chalmers; Ibrahim S Nasr; Richard J Brindle; John English; Sarah K Meredith; Nicholas J Reynolds; David de Berker; Peter S Mortimer; Hywel C Williams
Journal:  N Engl J Med       Date:  2013-05-02       Impact factor: 91.245

View more
  8 in total

1.  A Woman with Unilateral Rash and Fever: Cellulitis in the Setting of Lymphedema.

Authors:  Melissa Joseph; Marissa Camilon; Tarina Kang
Journal:  Case Rep Emerg Med       Date:  2015-06-11

2.  Impact of Compression Therapy on Cellulitis (ICTOC) in adults with chronic oedema: a randomised controlled trial protocol.

Authors:  Elizabeth Webb; Teresa Neeman; Jamie Gaida; Francis J Bowden; Virginia Mumford; Bernie Bissett
Journal:  BMJ Open       Date:  2019-08-15       Impact factor: 2.692

3.  In Search of Risk Factors for Recurrent Erysipelas and Cellulitis of the Lower Limb: A Cross-Sectional Study of Epidemiological Characteristics of Patients Hospitalized due to Skin and Soft-Tissue Infections.

Authors:  Mariusz Sapuła; Dagny Krankowska; Alicja Wiercińska-Drapało
Journal:  Interdiscip Perspect Infect Dis       Date:  2020-05-07

4.  Factors associated with acute and recurrent erysipelas in a young population: a retrospective of 147 cases.

Authors:  Amal Chamli; Kahena Jaber; Imene Ben Lagha; Malek Ben Slimane; Faten Rabhi; Nejib Doss; Mohamed Raouf Dhaoui
Journal:  Tunis Med       Date:  2021 Aout

Review 5.  Recurrent Cellulitis: Who is at Risk and How Effective is Antibiotic Prophylaxis?

Authors:  Bin S Ong; Ravindra Dotel; Vincent Jiu Jong Ngian
Journal:  Int J Gen Med       Date:  2022-08-10

6.  The effectiveness of erysipelas prophylaxis depends on the cumulative dose of benzathine penicillin G.

Authors:  Agnieszka Bednarska; Iwona Sosińska-Bryła; Paweł Grąbczewski; Regina Podlasin; Marcin Paciorek; Dominik Bursa; Małgorzata Hackiewicz; Michał Makowiecki; Andrzej Horban
Journal:  Dermatol Reports       Date:  2022-03-17

7.  Etiology of Cellulitis and Clinical Prediction of Streptococcal Disease: A Prospective Study.

Authors:  Trond Bruun; Oddvar Oppegaard; Bård R Kittang; Haima Mylvaganam; Nina Langeland; Steinar Skrede
Journal:  Open Forum Infect Dis       Date:  2015-11-25       Impact factor: 3.835

8.  Cellulitis in aged persons: a neglected infection in the literature.

Authors:  Anis Mzabi; Wafa Marrakchi; Zeineb Alaya; Fatma Ben Fredj; Amel Rezgui; Elyès Bouajina; Chedia Laouani Kechrid
Journal:  Pan Afr Med J       Date:  2017-06-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.